Literature DB >> 17048205

Screening for silent ischemia with coronary artery calcium and nuclear stress testing in nondiabetic patients prior to kidney transplant.

Emiliana Ferramosca1, Antonio Di Felice, Carlo Ratti, Guido Ligabue, Dalia Ibrahim, Maria Grazia Modena, Renato Romagnoli, Bruno Bagni, Alberto Albertazzi, Paolo Raggi.   

Abstract

Whether coronary artery calcium (CAC) screening in pretransplant patients may help predict silent myocardial ischemia is unknown. Accordingly, we performed CAC imaging on 46 nondiabetic patients awaiting kidneytransplant. All patients underwent multidetector computed tomography imaging for CAC quantification, and a vasodilator myocardial perfusion stress (MPS) test was performed only in patients with a total CAC score>300 or>100 in a single coronary artery. The mean patient's age was 46+/-14 years and the median dialysis vintage was 33 months (interquartile range 19-53). The median CAC score was 82 (interquartile range 0-700) and correlated with patients' age (p=0.006) and dialysis vintage (p=0.02). Nineteen patients qualified for MPS, but 5 refused the test. Of the remaining 14 patients, 7 patients had normal scans and 7 showed a minimal perfusion defect in the inferoposterior segment of the left ventricle. At the time of writing, 12 patients have undergone successful kidney transplantation without untoward complications. CAC screening does not appear to be associated with silent ischemia in pretransplant patients. Though CAC is extensive in dialysis patients, calcium may be associated with nonobstructive atherosclerotic lesions or calcification of the media layer of the vessel wall.

Entities:  

Mesh:

Year:  2006        PMID: 17048205

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  1 in total

1.  Hybrid myocardial imaging for risk stratification prior to kidney transplantation: added value of coronary calcium and epicardial adipose tissue.

Authors:  Cristina Karohl; Luis D'Marco; Antonio Bellasi; Paolo Raggi
Journal:  J Nucl Cardiol       Date:  2013-09-12       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.